Vion Pharmaceuticals may be delisted
New-haven based Vion Pharmaceuticals Inc., a developer of cancer therapies, may be delisted by Nasdaq because its equity has fallen below a minimum of $2.5 million in stockholders' equity.
In a letter from the Nasdaq Stock Market Inc., Vion failed to comply with its marketplace rule which requires a minimum of stockholder equity, or $35 million market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year.
As a result, Nasdaq is reviewing the company's eligibility for continued listing on The Nasdaq Capital Market. To facilitate this review, Vion has been asked to provide a specific plan to achieve and sustain compliance with all The Nasdaq Capital Market listing requirements by April 15, including the time frame for completion of the plan.
WBJ Web Partners
Most Recent
Most Recent
0 Comments